Research progress in molecular diagnosis and treatment of chordoma
-
摘要: 脊索瘤作为一种恶性程度较高的原发恶性肿瘤,起源于胚胎残余脊索组织,复发率高,预后差。目前相关研究已经发现包括Brachyury基因等多个分子及信号通路参与脊索瘤的发生发展,但其病因仍不明确。由于脊索瘤转移率高且对周围组织侵袭性较强,其治疗仍是目前亟待解决的一大难题。研究脊索瘤发生发展的关键分子及信号通路不仅有助于深入了解脊索瘤的发病机制,也为改善脊索瘤治疗现状提供了新的方向。本文从脊索瘤的分子信号学、临床诊断及治疗等方面对脊索瘤的研究进展进行论述。Abstract: Chordoma, as a highly malignant primary tumor, originates from residual embryonic spinal cord tissue, with a high recurrence rate and poor prognosis. Although current research has found that multiple molecules and signaling pathways, including the Brachyury gene, are involved in the occurrence and development of spinal cord tumors, their etiology is still unclear. Due to the strong metastasis and invasion of surrounding tissues, the treatment of spinal cord tumors remains a major challenge that urgently needs to be addressed. Identifying the key molecules and signaling pathways involved in the occurrence and development of spinal cord tumors can not only help to gain a deeper understanding of the pathogenesis of spinal cord tumors, but also provide new directions for improving the current status of spinal cord tumor treatment. This article reviews the research progress of chordoma from the aspects of molecular signaling, clinical diagnosis and treatment.
-
Keywords:
- chordoma /
- bone tumour /
- molecular biology /
- signaling pathway /
- treatment /
- operation
-
-
[1] Sahyouni R,Goshtasbi K,Mahmoodi A,et al.A historical recount of chordoma[J].J Neurosurg Spine,2018,28(4):422-428.
[2] Zuckerman SL,Lee SH,Chang GJ,et al.Outcomes of surgery for sacral chordoma and impact of complications:a report of 50 consecutive patients with long-term follow-up[J].Global Spine J,2021,11(5):740-750.
[3] Passer JZ,Alvarez-Breckenridge C,Rhines L,et al.Surgical management of skull base and spine chordomas[J].Curr Treat Options Oncol,2021,22(5):40.
[4] Napieralska A,Blamek S.Intracranial chordoma:radiosurgery,hypofractionated stereotactic radiotherapy and treatment outcomes[J].Rep Pract Oncol Radiother,2021,26(5):764-772.
[5] Berra LV,Familiari P,Palmieri M,et al.Sacral nerves reconstruction after surgical resection of a large sacral chordoma restores the urinary and sexual function and the anal continence[J].Neurospine,2022.19(1):155-162.
[6] Bai J,Li M,Shi J,et al.Mid-term follow-up surgical results in 284 cases of clival chordomas:the risk factors for outcome and tumor recurrence[J].Neurosurg Rev,2022,45(2):1451-1462.
[7] Cottone L,Cribbs AP,Khandelwal G,et al.Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death[J].Cancer Res,2020,80(20):4540-4551.
[8] de Almeida LGN,Thode H,Eslambolchi Y,et al.Matrix metalloproteinases:from molecular mechanisms to physiology,pathophysiology,and pharmacology[J].Pharmacol Rev,2022,74(3):712-768.
[9] Antonelli M,Raso A,Mascelli S,et al.SMARCB1/INI1 involvement in pediatric chordoma:a mutational and immunohistochemical analysis[J].Am J Surg Pathol,2017,41(1):56-61.
[10] Ma JP,Tian KB,Du J,et al.High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas[J].J Neurosurg,2020,132(1):140-149.
[11] Tsitouras V,Wang S,Dirks P,et al.Management and outcome of chordomas in the pediatric population:the hospital for sick children experience and review of the literature[J].J Clin Neurosci,2016,34:169-176.
[12] Chanplakorn P,Lertudomphonwanit T,Homcharoen W,et al.Results following surgical resection of recurrent chordoma of the spine:experience in a single institution[J].World J Surg Oncol,2020,18(1):228.
[13] Emija NK,Anda NP.Chordoma:To know means to recognize[J].Biochim Biophys Acta Rev Cancer,2022,1877(5):188796.
[14] Ghaith AK,Akinduro OO,Alexander AY,et al.Immunohistochemical markers predicting long-term recurrence following clival and spinal chordoma resection:a multicenter study[J].Neurosurg Focus,2023,54(6):E15.
[15] Gellner V,Tomazic PV,Lohberger B,et al.Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies[J].Sci Rep,2016,6:24195.
[16] Yadav R,Sharma MC,Malgulwar PB,et al.Prognostic value of MIB-1,p53,epidermal growth factor receptor,and INI1 in childhood chordomas[J].Neuro Oncol,2014,16(3):372-381.
[17] Li XF,Wang SJ,Chen Y,et al.Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence[J].Onkologie,2013,36(10):567-571.
[18] Masuelli L,Benvenuto M,Fantini M,et al.Knockdown of MMP16 inhibits cell proliferation and invasion in chordoma in vitro[J].J Biol Regul Homeost Agents,2020,34(6):2263-2270.
[19] Froehlich EV,Scheipl S,Lazàry A,et al.Expression of ezrin,MMP-9,and COX-2 in 50 chordoma specimens:a clinical and immunohistochemical analysis[J].Spine,2012,37(13):E757-E767.
[20] Liu JQ,Wang ZL,Xu C,et al.Solamargine inhibits proliferation and promotes apoptosis of CM-319 human chordoma cells through suppression of Notch pathway[J].Transl Cancer Res,2019,8(2):509-519.
[21] Jahanafrooz Z,Stallinger A,Anders I,et al.Influence of silibinin and β-β-dimethylacrylshikonin on chordoma cells[J].Phytomedicine,2018,49:32-40.
[22] Shen XH,Cui XS,Lee SH,et al.Interleukin-6 enhances porcine parthenote development in vitro,through the IL-6/Stat3 signaling pathway[J].J Reprod Dev,2012,58(4):453-460.
[23] Akhavan-Sigari R,Gaab MR,Rohde V,et al.Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma[J].Eur Spine J,2014,23(11):2416-2422.
[24] Ma YL,Zhu B,Liu XG,et al.iASPP overexpression is associated with clinical outcome in spinal chordoma and influences cellular proliferation,invasion,and sensitivity to cisplatinin vitro[J].Oncotarget,2017,8(40):68365-68380.
[25] Sun SJ,Wu YR,Maimaitijiang A,et al.Ferroptotic cardiomyocyte-derived exosomes promote cardiac macrophage M1 polarization during myocardial infarction[J].PeerJ,2022,10:e13717.
[26] Akhavan-Sigari R,Gaab MR,Rohde V,et al.Expression of PDGFR-α,EGFR and c-MET in spinal chordoma:a series of 52 patients[J].Anticancer Res,2014.34(2):623-630.
[27] Huang W,Yan YG,Wang WJ,et al.Development and validation of a 6-miRNA prognostic signature in spinal chordoma[J].Front Oncol,2020,10:556902.
[28] Al Shihabi A,Davarifar A,Nguyen HTL,et al.Personalized chordoma organoids for drug discovery studies[J].Sci Adv,2022,8(7):eabl3674.
[29] Michmerhuizen NL,Owen JH,Heft Neal ME,et al.Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy[J].J Neurooncol,2020,147(1):25-35.
[30] Tamborini E,Virdis E,Negri T,et al.,Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas[J].Neuro Oncol,2010.12(8):776-789.
[31] Akhavan-Sigari R,Schulz-Schaeffer W,Angelika Harcej A,et al.The importance of the hedgehog signaling pathway in tumorigenesis of spinal and cranial chordoma[J].J Clin Med,2019,8(2):248.
[32] Chen KW,Chen H,Zhang K,et al.MicroRNA profiling and bioinformatics analyses reveal the potential roles of microRNAs in chordoma[J].Oncol Lett,2017:5533-5539.
[33] Zuccato JA,Patil V,Mansouri S,et al.DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma[J].Neuro Oncol,2022,24(3):442-454.
[34] Yao J,Wu XJ.Upregulation of miR-149-3p suppresses spinal chordoma malignancy by targeting Smad3[J].Onco Targets Ther,2019,12:9987-9997.
[35] Kremenevski N,Schlaffer SM,Coras R,et al.Skull base chordomas and chondrosarcomas[J].Neuroendocrinology,2020,110(9/10):836-847.
[36] Batista KMP,Reyes KYA,Lopez FP,et al.Immunophenotypic features of dedifferentiated skull base chordoma:an insight into the intratumoural heterogeneity[J].Contemp Oncol (Pozn),2017,21(4):267-273.
[37] 臧乐源,初同伟.原发性骶骨肿瘤的外科治疗进展[J].中国修复重建外科杂志,2016,30(4):518-522. [38] Sanusi O,Arnaout O,Rahme RJ,et al.Surgical resection and adjuvant radiation therapy in the treatment of skull base chordomas[J].World Neurosurg,2018,115:e13-e21.
[39] Zoli M,Milanese L,Bonfatti R,et al.Clival chordomas:considerations after 16 years of endoscopic endonasal surgery[J].J Neurosurg,2018,128(2):329-338.
[40] 李储忠,张亚卓.颅底脊索瘤临床诊疗进展[J].中国耳鼻咽喉颅底外科杂志,2019,25(3):225-227. [41] Moune MY,Sayore CM,Hemama M,et al.Surgical management of a thoracic chordoma:a case report and literature review[J].Surg Neurol Int,2022,13:63.
[42] Sharma R,Mukherjee D,Arnav A,et al.Surgical and functional outcomes of en bloc resection of sacral chordoma:a retrospective analysis[J].Indian J Surg Oncol,2021,12(4):750-758.
[43] Hosalkar HS,Jones KJ,King JJ,et al.Serial arterial embolization for large sacral giant-cell tumors:mid- to long-term results[J].Spine (Phila Pa 1976),2007,32(10):1107-1115.
[44] D'Alessandris QG,Offi M,Caccavella VM,et al.Comparison of combined anterior-posterior and posterior-only approaches for lumbosacral chordomas:a systematic review and meta-analysis of surgical and clinical outcomes[J].Neurosurg Rev,2022,45(3):2005-2012.
[45] Dubory A,Missenard G,Lambert B,et al."En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach:a monocentric retrospective review about 29 cases[J].Eur Spine J,2014,23(9):1940-1948.
[46] Zheng LP,Li ZQ,Li Q,et al.Finite element analysis of lumbosacral reconstruction after partial sacrectomy[J].Med Sci Monit,2014,20:889-893.
[47] Rotondo RL,Folkert W,Liebsch NJ,et al.High-dose proton-based radiation therapy in the management of spine chordomas:outcomes and clinicopathological prognostic factors[J].J Neurosurg Spine,2015,23(6):788-797.
计量
- 文章访问数: 121
- HTML全文浏览量: 2
- PDF下载量: 24
下载:
.png)
